We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. 858-366-3243, Internet Explorer presents a security risk. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). To ensure the most secure and best overall experience on our website, we recommend the latest versions of. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. Pay, Holidays and PTO appear to be very good. 917-322-2571, Internet Explorer presents a security risk. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). 301-968-3501, ITI Media: The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ICT has established a broad portfolio of CAR-T products to treat cancer patients. For more information, please visit www.immunomix.com. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. Contact Email info@immunic.de. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. ITI-1001 GBM - pDNA. Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. Bard (Becton, Dickinson and Company). Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. 438 followers 429 connections. Companies. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. We are based at the Translation & Innovation Hub that sits on Imperial College London's 23-acre White City Campus development in west . The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. Immunomic Therapeutics is a biotech company committed to patients. Coordinates: 245831.9N 1213154.0E. The company was founded in 2005 and is based in Lancaster, Pennsylvania. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). HLB also secured an option to make further investment into the company in the months ahead. Immunomic Therapeutics General Information. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. Immunomic Therapeutics' nucleic acid vaccines have the . Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Operating Status Active. Melody Carey Book the hotel with real traveler reviews, ratings and latest pictures of Chinatrust Executive House Hsin-Tien. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Request a free trial. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. Katie Pearce. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. View detailed 028300.KR description & address. Melissa Kemp Our goal is to overcome the limitations of current immuno-oncology therapies by . To ensure the most secure and best overall experience on our website, we recommend the latest versions of. It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. Description. 301-968-3501 Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI maintains its headquarters in Rockville, Maryland. Report this profile . Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics, Inc. may be just for you. The UNITE platform can result in a number of downstream effects: CD4+ memory, cytokine production, and a potent antibody response. The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. For more information, please visit www.immunomix.com. ITI-2000 HPV+ Tumors. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. This is the Immunomic Therapeutics company profile. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. mcarey@rxir.com View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. J Immunol. J Immunol Res. November 30, 2021, 7:01 PM UTC. In addition, ITI-1001 represents a far more cost-effective approach. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Checkmate-548 was the most recent hope for Opdivo in glioblastoma following the failures, in 2017 and 2019 respectively, of Checkmate-143 in the second-line setting and Checkmate-498 in first-line. Last Funding Type Venture - Series Unknown. mkemp@immunomix.com mcarey@rxir.com 2017 Apr 15;23(8):1898-1909. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. 2006 Aug 15;177(4):2265-75. 2016;2016:4857869. Clin Cancer Res. Immunomic Therapeutics Announces Presentation on Nucleic Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs, Northeastern US Biotechnology Female Founded Companies. Animal Health All. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. We provide a professional and challenging work environment . MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. Jan 30, 2015. This employer has not claimed their Employer Profile and is missing out on connecting with our community. April 23, 2020 04:00 PM Eastern Daylight Time. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. 2003 Sep 26;278(39):37926-36. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. The financing will also enable Immunomic to expand its team and infrastructure to support the future growth of the company. Hum Vaccin Immunother. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. Headquarters Location. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. Email credentials to careers@immunomix.com. Background. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you.